Company: Better Medicine
CEO: Priit Salumaa, Helena Ije (COO), Bohdan Petryshak (Chief AI Engineer), Martin Reim (Chief Medical Officer), Dmytro Fishman (Chief Science Officer)
Website: https://bettermedicine.ai/
About Better Medicine
Better Medicine, an Estonian medical technology company established in 2020, creates AI-powered software solutions that have earned CE certification for enhancing cancer screening and diagnostic processes in medical imaging. The company’s core offering, the BMVision system, seamlessly connects with existing radiologist workflows to identify and analyse cancer-related abnormalities, with an initial focus on renal lesions. The startup maintains operations in six nations and partners with medical facilities and academic centres throughout Europe, the United Kingdom, South Africa, and the United States.
Medical imaging departments globally are experiencing unprecedented strain due to increasing scan volumes paired with insufficient numbers of trained specialists. The United Kingdom exemplifies this crisis with only 7 imaging specialists available per 100,000 residents. This workforce shortage leads to diagnostic delays, overlooked conditions, and professional exhaustion. Worldwide, healthcare systems dedicate approximately 12 million hours annually to manual lesion analysis and documentation.
To tackle these systemic issues, Better Medicine has developed clinically proven artificial intelligence algorithms that support imaging specialists in identifying, analysing, and documenting cancer-related findings in computed tomography examinations. The platform provides automated lesion identification and analysis capabilities while maintaining compatibility with existing medical imaging systems, including picture archiving and communication systems and diagnostic viewers.
The company’s primary solution, BMVision Kidney, has achieved CE marking as a Class IIa medical device under European Union Medical Device Regulation (MDR 2017/745), establishing it as the inaugural CE-approved AI-driven renal cancer screening solution meeting these regulatory standards. Clinical testing has demonstrated that imaging specialists utilising BMVision experience time reductions of up to 52% while maintaining a 99.2% identification accuracy rate.
BMVision Kidney employs advanced neural networks trained on comprehensive clinical imaging databases to recognise malignant renal abnormalities. Research trials have shown the system achieves 96% independent diagnostic accuracy and 99.2% identification success when used alongside professional radiologist evaluation. An additional feature, BM iMeasure, provides semi-automated lesion analysis and standardised documentation capabilities.
Check out what TechRound can do for your business: SEO, PR, HR Software, Payroll Software, IT, VoIP.